(Q37823438)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Anthony P. Conley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Wei-Lien Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

David Reynoso

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Laura Nolden

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Suzanne George

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jonathan C Trent

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

24 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

67 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

S15-24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Molecular pathobiology of gastrointestinal stromal sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1513-8

10.1007/S00280-010-1513-8

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21181476%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference